得克萨斯州 的 多发性骨髓瘤 临床试验
得克萨斯州 有 53 项针对 多发性骨髓瘤 的研究正在招募参与者。
得克萨斯州 的城市
官方研究文本（英文）
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Austin
- Research Site, Dallas
- Research Site, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- MD Anderson Cancer Center, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT05652335A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
- Joe Arrington Cancer Research Treatment Center, Lubbock
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- St. David's South Austin Medical Center, Austin
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
- 以及另外 2 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07258511A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- MD Anderson Cancer Center, Houston
招募中4 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05201781A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- The University of Texas MD Anderson Cancer Center, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05623020A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Baylor University Medical Center, Dallas
- Joe Arrington Cancer Research Treatment Center, Lubbock
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07073547A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- MD Anderson, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07336472A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- The University of Texas MD Anderson Cancer Center, Houston
招募中2 期
12 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Texas Oncology - The Woodlands /ID# 278726, The Woodlands
- Texas Oncology - Northeast Texas /ID# 278725, Tyler
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT07648264A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
- MD Anderson Cancer Center, Houston
招募中2 期
所有年龄段 · 所有性别 · 更新于 2026年9月18日 · NCT07382739Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- MD Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月17日 · NCT04879043A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Texas MD Anderson Cancer Center, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT06615479A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06953960Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- UT Southwestern Medical Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06297226A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Texas MD Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月2日 · NCT06988488A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月27日 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center Infusion, Houston
- 以及另外 9 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月24日 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Fort Worth
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月19日 · NCT05714839A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT05651932A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- MD Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Austin
- Research Site, Dallas
- Research Site, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月17日 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Dallas
- Research Site, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月14日 · NCT07764978Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
- MD Anderson Cancer Center, Houston
招募中2 期欢迎健康志愿者
18 岁及以上 · 所有性别 · 更新于 2026年8月14日 · NCT05091372A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Baylor University Medical Center, Dallas
- Houston Methodist Hospital, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月12日 · NCT07280013Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
- M D Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月10日 · NCT06105554Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- MD Anderson Cancer Center, Houston
招募中2 期
18 至 75 岁 · 所有性别 · 更新于 2026年8月10日 · NCT06207799Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
招募中1/2 期
12 至 80 岁 · 所有性别 · 更新于 2026年8月7日 · NCT05092451A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- START San Antonio, San Antonio
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月6日 · NCT07284758A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年7月21日 · NCT06892522A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Texas MD Anderson Cancer Center, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月16日 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Texas Oncology - Central/South Texas /ID# 268563, Austin
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
- Oncology Consultants /ID# 268323, Houston
- 以及另外 1 项
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月13日 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of Texas Southwestern, Dallas
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月8日 · NCT05137054Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- St. David's South Austin Medical Center, Austin
招募中4 期
18 岁及以上 · 所有性别 · 更新于 2026年7月1日 · NCT06057402Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- MD Anderson in The Woodlands, Conroe
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- 以及另外 6 项
招募中3 期
所有年龄段 · 所有性别 · 更新于 2026年6月10日 · NCT05561387Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
- M D Anderson Cancer Center, Houston
招募中2 期
18 至 72 岁 · 所有性别 · 更新于 2026年6月8日 · NCT05776979Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Houston Methodist Hospital, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年6月4日 · NCT05243797数据来自 ClinicalTrials.gov，检索日期：2026年10月2日。每项研究自行设定入选标准，由研究团队决定谁能参与。